Michael J. Thirman

TL;DR: In previously untreated patients with confirmed AML who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of remission was higher among patients who received azacitidine plus venetoclax than among those who received zsitidine alone.

TL;DR: The ability to detect an MLL gene rearrangement rapidly and reliably, especially in patients with limited material for cytogenetic analysis, should make it possible to identify patients who have a poor prognosis and therefore require aggressive chemotherapy or marrow transplantation.

TL;DR: This combination phase 1b study enrolled previously untreated patients aged 65 years and over with acute myeloid leukaemia who were ineligible for standard induction therapy and suggested synergy between hypomethylating agents and venetoclax to determine the maximum tolerated dose and recommended phase 2 dose and analysed safety, pharmacokinetics, and anti-leukaemic activity in all patients.

TL;DR: It is demonstrated that specific alterations in miRNA expression distinguish AMLs with common translocations and imply that the deregulation of specific miRNAs may play a role in the development of leukemia with these associated genetic rearrangements.

TL;DR: The association of exposure to topo II- reactive chemotherapy with 11q23 rearrangements involving the MLL gene in t-AML suggests thatTopo II may play a role in the aberrant recombination events that occur in this region both in AML de novo and in t -AML.